A Dose-Ranging, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Tezepelumab Alone or Combined With Topical Corticosteroids in Moderate-to-Severe Atopic Dermatitis
Latest Information Update: 06 Sep 2022
At a glance
- Drugs Tezepelumab (Primary) ; Corticosteroid
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors Amgen
- 30 Aug 2022 According to an Amgen media release, data from this trial will be presented at the 31st European Academy of Dermatology and Venereology (EADV) 2022.
- 04 May 2021 This trial was discontinued in Poland according to European Clinical Trials Database.
- 11 Feb 2021 This trial was discontinued in Germany (end date: 2020-12-22) according to European Clinical Trials Database.